Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Dec 1;114(5):910-918.
doi: 10.1016/j.ijrobp.2022.05.023. Epub 2022 Jun 9.

Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND

Alexander D Sherry  1 , Tharakeswara K Bathala  2 , Suyu Liu  3 , Bryan M Fellman  3 , Stephen G Chun  1 , Nikesh Jasani  4 , B Ashleigh Guadagnolo  1 , Anuja Jhingran  1 , Jay P Reddy  1 , Paul G Corn  5 , Amishi Y Shah  5 , Kelsey W Kaiser  1 , Amol J Ghia  1 , Daniel R Gomez  6 , Chad Tang  7
Affiliations
Clinical Trial

Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND

Alexander D Sherry et al. Int J Radiat Oncol Biol Phys. .

Abstract

Purpose: The benefit of local consolidative therapy (LCT) for oligometastasis across histologies remains uncertain. EXTernal beam radiation to Eliminate Nominal metastatic Disease (EXTEND; NCT03599765) is a randomized phase 2 basket trial evaluating the effectiveness of LCT for oligometastatic solid tumors. We report here the prospective results of the single-arm "lead-in" phase intended to identify histologies most likely to accrue to histology-specific endpoints in the randomized phase.

Methods and materials: Eligible histologies included colorectal, sarcoma, lung, head and neck, ovarian, renal, melanoma, pancreatic, prostate, cervix/uterine, breast, and hepatobiliary. Patients received LCT to all sites of active metastatic disease and primary/regional disease (as applicable) plus standard-of-care systemic therapy or observation. The primary endpoint in EXTEND was progression-free survival (PFS), and the primary endpoint of the lead-phase was histology-specific accrual feasibility. Adverse events were graded by Common Terminology Criteria for Adverse Events version 4.0.

Results: From August 2018 through January 2019, 50 patients were enrolled and 49 received definitive LCT. Prostate, breast, and kidney were the highest enrolling histologies and identified for independent accrual in the randomization phase. Most patients (73%) had 1 or 2 metastases, most often in lung or bone (79%), and received ablative radiation (62%). Median follow-up for censored patients was 38 months (range, 16-42 months). Median PFS was 13 months (95% confidence interval, 9-24), 3-year overall survival rate was 73% (95% confidence interval, 57%-83%), and local control rate was 98% (93 of 95 tumors). Two patients (4%) had Common Terminology Criteria for Adverse Events grade 3 toxic effects related to LCT; no patient had grade 4 or 5 toxic effects.

Conclusions: The prospective lead-in phase of the EXTEND basket trial demonstrated feasible accrual, encouraging PFS, and low rates of severe toxic effects at mature follow-up. The randomized phase is ongoing with histology-based baskets that will provide histology-specific evidence for LCT in oligometastatic disease.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier plots of (A) overall survival and (B) progression-free survival. Number at risk and number censored are shown below the x axis. Shaded regions denote 95% confidence intervals. Tick marks indicate censoring.
Figure 2.
Figure 2.
Swimmer plot depicting patient-level primary tumor histology, extent of disease, pre-treatment, and disease outcomes over time.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8–10. - PubMed
    1. Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell 2009;139:1315–26. - PMC - PubMed
    1. Gundem G, Van Loo P, Kremeyer B, et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015;520:353–7. - PMC - PubMed
    1. Norton L, Simon R. Growth curve of an experimental solid tumor following radiotherapy. J Natl Cancer Inst 1977;58:1735–41. - PubMed
    1. Patel RR, Verma V, Barsoumian HB, et al. Use of Multi-Site Radiation Therapy for Systemic Disease Control. Int J Radiat Oncol Biol Phys 2021;109:352–64. - PMC - PubMed

Publication types